Katarzyna Kaczmarek Michaels
Overview
Explore the profile of Katarzyna Kaczmarek Michaels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramezani-Rad P, Marina-Zarate E, Maiorino L, Myers A, Michaels K, Pires I, et al.
J Clin Invest
. 2025 Mar;
PMID: 40036068
The induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play a role as drivers of such responses. Despite advances in vaccine strategies, a...
2.
Ramezani-Rad P, Cottrell C, Marina-Zarate E, Liguori A, Landais E, Torres J, et al.
bioRxiv
. 2025 Feb;
PMID: 39896562
A protective vaccine against HIV will likely need to induce broadly neutralizing antibodies (bnAbs) that engage relatively conserved epitopes on the HIV envelope glycoprotein (Env) trimer. Nearly all vaccine strategies...
3.
Buckley M, Arainga M, Maiorino L, Pires I, Kim B, Michaels K, et al.
Mol Ther
. 2025 Jan;
33(3):1105-1117.
PMID: 39797396
mRNA delivered using lipid nanoparticles (LNPs) has become an important subunit vaccine modality, but mechanisms of action for mRNA vaccines remain incompletely understood. Here, we synthesized a metal chelator-lipid conjugate...
4.
Pratap P, Cottrell C, Quinn J, Carnathan D, Bader D, Tran A, et al.
bioRxiv
. 2024 Dec;
PMID: 39651156
During infection, the fusion peptide (FP) of HIV envelope glycoprotein (Env) serves a central role in viral fusion with the host cell. As such, the FP is highly conserved and...
5.
Madden P, Marina-Zarate E, Rodrigues K, Steichen J, Shil M, Ni K, et al.
bioRxiv
. 2024 Dec;
PMID: 39651117
Rare B cells can have special pathogen-recognition features giving them the potential to make outsized contributions to protective immunity. However, rare naive B cells infrequently participate in immune responses. We...
6.
Ramezani-Rad P, Marina-Zarate E, Maiorino L, Myers A, Michaels K, Pires I, et al.
bioRxiv
. 2024 Aug;
PMID: 39211109
The induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play an important role as drivers of such responses. Despite advances in vaccine strategies,...
7.
Buckley M, Arainga M, Maiorino L, Pires I, Kim B, Michaels K, et al.
bioRxiv
. 2024 Jul;
PMID: 38979236
mRNA delivered using lipid nanoparticles (LNPs) has become an important subunit vaccine modality, but mechanisms of action for mRNA vaccines remain incompletely understood. Here, we synthesized a metal chelator-lipid conjugate...
8.
Graber J, Hoskinson D, Liu H, Michaels K, Benson P, Maki N, et al.
Genetics
. 2023 Nov;
226(2).
PMID: 37967370
The Pcf11 protein is an essential subunit of the large complex that cleaves and polyadenylates eukaryotic mRNA precursor. It has also been functionally linked to gene-looping, termination of RNA Polymerase...
9.
Phung I, Rodrigues K, Marina-Zarate E, Maiorino L, Pahar B, Lee W, et al.
Nat Commun
. 2023 Nov;
14(1):7107.
PMID: 37925510
Adjuvants and antigen delivery kinetics can profoundly influence B cell responses and should be critically considered in rational vaccine design, particularly for difficult neutralizing antibody targets such as human immunodeficiency...
10.
Dalecki A, Greer B, Duverger A, Strange E, Carlin E, Wagner F, et al.
J Virol
. 2022 Jan;
96(5):e0197421.
PMID: 35019721
The development of therapies to eliminate the latent HIV-1 reservoir is hampered by our incomplete understanding of the biomolecular mechanism governing HIV-1 latency. To further complicate matters, recent single-cell RNA...